Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

ClinicalTrials.gov ID: NCT00406068

Public ClinicalTrials.gov record NCT00406068. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG

Study identification

NCT ID: NCT00406068
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Bioniche Life Sciences Inc.; Industry
Enrollment: 129 participants

Conditions and interventions

Conditions

Bladder Neoplasms

Interventions

Mycobacterial cell wall-DNA complex Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2006
Primary completion: Jun 30, 2011
Completion: Jun 30, 2011
Last update posted: Jul 27, 2016

2006 – 2011

United States locations

U.S. sites: 20
U.S. states: 14
U.S. cities: 20

Facility	City	State	ZIP	Site status
BCG Oncology	Phoenix	Arizona	85032	—
San Diego Clinical Trials	San Diego	California	92120	—
Connecticut Urological Research at Grove Hill	New Britain	Connecticut	06052	—
University of Miami School of Medicine	Miami	Florida	33136	—
Winter Park Urology Associates P.A.	Orlando	Florida	32803	—
The University of Chicago Hospitals	Chicago	Illinois	60637	—
Welborn Clinic	Evansville	Indiana	47713	—
Johns Hopkins University	Baltimore	Maryland	21231	—
Chesapeake Urology Research Associates	Towson	Maryland	21204	—
Sheldon J Freedman, MD, Ltd	Las Vegas	Nevada	89148	—
Delaware Valley Urology, LLC-Voorhees	Voorhees Township	New Jersey	08043	—
Memorial Sloan Kettering Cancer Centre	New York	New York	10021	—
Hudson Valley Urology	Poughkeepsie	New York	12601	—
University of Rochester Medical Center	Rochester	New York	14642	—
Triangle Urology Group	Pittsburgh	Pennsylvania	15212	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232	—
Urology Clinics of North Texas, P.A.	Dallas	Texas	75231	—
M.D. Anderson Cancer Center	Houston	Texas	77030	—
Urology San Antonio Research, PA	San Antonio	Texas	78229	—
Sentara Medical Group - Urology of Virginia, PC	Norfolk	Virginia	23502	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00406068, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 27, 2016 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00406068 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →